GLP-1 and incretin · compound · checked 2026-10-09

Retatrutide

Retatrutide is a study drug that hits GLP-1, GIP, and glucagon receptors. FDA has not approved it. FDA says it cannot be used in compounding under federal law. Phase 2 and the 2026 TRIUMPH-2 Phase 3 paper report weight and blood-sugar results in defined trial groups. Those results do not travel to research-market vials. Keep the paper.

Open the Retatrutide calculator How the math works

Last checked Oct 9, 2026 by PepBear. Not medical advice.

FDA product: not approved
Compounding: restricted
Research: investigational
Sport: unknown

What is Retatrutide?

Seller aliases include R-10, R-30, and several milligram labels. Those names are not proven matches for Lilly trial material. Oral, nasal, or “premium” research listings do not inherit trial results. The mechanism language here comes from the study program. It is not a wellness claim.

Investigational agonist of GLP-1, GIP and glucagon receptors.

Regulatory status, dated 2026-10-09

FDA product approval

not approved. FDA identifies this investigational substance as unapproved.

Compounding

restricted. FDA states this substance cannot be used in compounding under federal law.

Research

investigational. Human obesity trials; trial findings do not authorize unsupervised use.

Sport

unknown. Not individually verified; consult the current sport rules. Absence of a listing is not permission.

What the cited papers actually measured

The 2023 Phase 2 obesity paper (PMID 37366315) and the September 2026 TRIUMPH-2 Phase 3 report (PMID 42810372) are the cited human trials. TRIUMPH-2 randomized 1,152 adults with obesity and type 2 diabetes over 80 weeks. Stomach issues, low blood pressure, and odd skin sensation showed up more often with retatrutide than control in that paper. Different ways of counting change the headline percent. The sponsor paid for the trial and used controlled study material. A gray-market R-30 vial is not that product. FDA’s unapproved GLP-1 statement covers safety of unapproved versions used for weight loss.

We mark the cited papers as B. That is our label for how strong those papers are. It does not say the compound works.

human-trial

TRIUMPH-2 reported weight reduction at 80 weeks in 1,152 randomized adults with obesity and type 2 diabetes; gastrointestinal adverse events, low blood pressure and altered sensation were more frequent with retatrutide.

Adults with obesity and type 2 diabetes; published online September 29, 2026. Sponsor-funded trial of controlled study material. Results do not establish approval or equivalence of commercial research preparations. Different statistical estimands yield different headline weight-loss percentages.

How long it lasts, how you store it, listed sizes

The catalog does not record a single hour value. No verified formulation-specific human estimate in this source set; no guessed value is supplied.

The vendor file lists 6 mg, 10 mg, 12 mg, and 30 mg research sizes. Trial storage is not a home plan. Read the label on the vial you hold. Shelf the paper. An R-30 listing is a seller title, and the TRIUMPH-2 paper measured a defined study product over 80 weeks in 1,152 adults, so those two objects stay on separate shelves.

U-100 math for listed Retatrutide sizes. Each cell is micrograms per syringe mark if you add that much liquid. The table does the same math as the calculator. It does not pick an amount for you.

Micrograms per U-100 unit (100 marks / mL)
Listed vial	1 mL liquid	2 mL liquid	3 mL liquid
6 mg	60	30	20
10 mg	100	50	33.3
12 mg	120	60	40
30 mg	300	150	100

Risks and mix-ups already on the record

Safety is incomplete; absence of reports does not establish safety.
Phase 3 reports include hypotension and dysesthesia (altered sensation), alongside gastrointestinal adverse effects.
Unknown or incomplete for research formulations; this is not a clearance for use.
Unknown or incomplete; do not infer compatibility with medications or other substances.

People using PepBear often log: Dated weight, symptoms and clinician-directed metabolic records, alongside other medicines and activity. Record missing observations and changes in appetite, gastrointestinal symptoms and sensation; the app does not infer a treatment effect.

Sources

Primary evidence or regulator source · checked 2026-10-09
FDA unapproved GLP-1 safety statement · checked 2026-10-09
TRIUMPH-2: peer-reviewed Phase 3 results (September 2026) · checked 2026-10-09
ClinicalTrials.gov retatrutide records · checked 2026-10-09

Questions people ask

Is retatrutide approved in 2026?

As of Oct 9, 2026 the catalog records it as not approved. FDA says compounding is restricted under federal law.

Can a mix chart replace the trial amount?

Trial amounts belong to the cited protocol and study material. The chart only turns a labeled vial mass and a liquid volume into U-100 units for numbers you type.

A licensed clinician must interpret the evidence for your situation. This entry provides education, not treatment instructions. Not medical advice. PepBear does not pick a dose, a cycle, or a seller.